BeiGene Ltd and EUSA Pharma Product QARZIBA® Approval from China NMPA. See Also: Sagimet Sciences and NASH  

BeiGene Ltd and EUSA Pharma Receive Approval from China NMPA for QARZIBA® 

BeiGene Ltd (BGNE) and EUSA Pharma announced that China National Medical Products Administration (NMPA) has granted QARZIBA® (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response followed by myeloablative therapy and stem cell transplantation, as well as for patients with a history of relapsed or refractory (R/R) neuroblastoma with or without the residual disease. Dinutuximab beta is targeted immunotherapy approved by the European Medicines Agency (EMA).

From BeiGene Ltd and EUSA Pharma

Xiaobin Wu, Ph.D., President, Chief Operating Officer and General Manager of China at BeiGene, commented, “Dinutuximab beta represents an important biologic therapy for pediatric patients in China, having been listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA. For these young patients fighting neuroblastoma in China, we are proud to bring the first approved treatment.”

Leave a Reply